Trials / Completed
CompletedNCT04898387
Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 554 (actual)
- Sponsor
- Laboratoires Thea · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate the non-inferiority of T4030 unpreserved eye drops compared to Ganfort® UD in terms of efficacy.
Detailed description
Efficacy Parameters IOP assessment in each eye
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Bimatoprost Timolol (T4030) | Eye drop |
| COMBINATION_PRODUCT | Bimatoprost Timolol (Ganfort) | Eye drop |
Timeline
- Start date
- 2021-03-26
- Primary completion
- 2023-04-13
- Completion
- 2023-05-30
- First posted
- 2021-05-24
- Last updated
- 2023-07-21
Locations
1 site across 1 country: Bulgaria
Source: ClinicalTrials.gov record NCT04898387. Inclusion in this directory is not an endorsement.